Multigene Copy Number Alteration Risk Score Biomarker–Based Enrichment Study Designs in Metastatic Castrate-Resistant Prostate Cancer
A plasma multi-CNA risk score classifier can feasibly be leveraged to design an enrichment trial in mCRPC. Enriching 25% of patients screened with a risk score >1 was observed to be optimal for obtaining an adequately powered, biomarker-based mCRPC-enriched clinical trial.
Authors
- Manish Kohli (ORCID: https://orcid.org/0000-0002-9735-6614)
- Yeonjung Jo (ORCID: https://orcid.org/0000-0002-1630-2957)
- Jonathan Chipman
- Benjamin Haaland (ORCID: https://orcid.org/0000-0002-6270-6303)
- Tom Greene (ORCID: https://orcid.org/0000-0002-0053-485X)
Institutions
- University of Utah (US)
- Huntsman Cancer Institute (US)
- TetraLogic Pharmaceuticals (United States) (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1200/po-24-00399
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.42